🔍
Search Results - inflammatory+bowel+disease+(ibd)
4
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Treatment of Irritable Bowel Syndrome with Molybdenum
Unmet NeedIrritable Bowel Syndrome is a chronic and incurable gastrointestinal disorder that affects 3-20% of Americans depending on certain sociocultural and comorbid factors. A poorly understood condition, current treatments consist of antispasmodics, antidiarrheals, and dietary restrictions. Unable to alleviate all its symptoms, researchers are in...
Published: 3/13/2025
|
Inventor(s):
Pankaj Pasricha
,
Lian Sheng Liu
,
Qian Li
,
Alfred Spormann
Keywords(s):
Disease Indication
,
Gastrointestinal Disorders
,
Inflammatory Bowel Disease (IBD)
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Clinical and Disease Specializations > Gastroenterology > Irritable Bowel Disease
Inflammatory Bowel Disease (IBD)
: New Cytokine Biomarkers
C10931: Markers for Diagnosis and/or Prognosis of Irritable Bowel Disease and Syndrome Value Proposition: - The identified markers may be combined to optimize sensitivity and specificity. - These markers may be used in ELISA or Chip format. - Markers have been validated using colonic tissue biopsy samples. - Predicate technology and CPT codes already...
Published: 3/13/2025
|
Inventor(s):
Michael Centola
,
Nicholas Knowlton
,
Xuhang Li
,
Philip Alex
Keywords(s):
Biomarker
,
Chronic Inflammatory Diseases
,
Clinical Diagnostics
,
Diagnostic Biomarker
,
Disease Indication
,
Gastrointestinal Disorders
,
In Vitro Diagnostics
,
Inflammatory Bowel Disease
,
Inflammatory Bowel Disease (IBD)
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease
,
Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases
,
Clinical and Disease Specializations > Rare Diseases
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Diagnostics > Diagnostic Biomarkers
,
Technology Classifications > Diagnostics > In Vitro Diagnostics
,
Technology Classifications > Diagnostics
,
Clinical and Disease Specializations > Gastroenterology
,
Clinical and Disease Specializations > Inflammation
Identification of Novel Serological Biomarkers for Inflammatory Bowel Disease Using E.coli Proteome Chip
C10584: Novel Diagnostics for IBDNovelty: This technology involves use of novel E. coli proteome chip to diagnose, monitor and select appropriate treatments for patients suffering from
inflammatory bowel disease (IBD)
.Value Proposition: Current diagnostic methods for inflammatory bowel disease are invasive and patients find these tests unpleasant. The...
Published: 3/13/2025
|
Inventor(s):
Heng Zhu
,
Xuhang Li
Keywords(s):
Biomarker
,
Chronic Inflammatory Diseases
,
Clinical Diagnostics
,
Diagnostic Biomarker
,
Disease Indication
,
Gastrointestinal Disorders
,
In Vitro Diagnostics
,
Inflammatory Bowel Disease
,
Inflammatory Bowel Disease (IBD)
,
Inflammatory Disorders
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease
,
Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases
,
Clinical and Disease Specializations > Rare Diseases
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Diagnostics > Diagnostic Biomarkers
,
Technology Classifications > Diagnostics > In Vitro Diagnostics
,
Technology Classifications > Diagnostics
,
Clinical and Disease Specializations > Gastroenterology
,
Clinical and Disease Specializations > Inflammation
PNU-120596 and 3-(2,4-dimethoxybenzylidene) Anabaseine (GTS-21) (both nAchRa7 agonists) and Methyllycaconitine (anAchRa7 antagonist), are Highly Effective Drugs in Therapy of Ulcerative Colitis (UC) and Crohn's Disease (CD)
C10382: Breakthrough Therapeutic for Inflammatory Bowel Diseases (IBD)Novelty: This technology identifies a nicotinic acetylcholine receptor isoform (nAChR7) that has a prevalent role in affecting
Inflammatory Bowel Disease (IBD)
, as well as several agonist/antagonists to nAChR7, that are highly effective in both the prevention and therapy of ulcerative...
Published: 3/13/2025
|
Inventor(s):
Philip Alex
,
Michael Centola
,
Xuhang Li
Keywords(s):
Chronic Inflammatory Diseases
,
Combination
,
Crohn's disease
,
Crohn's Disease
,
Disease Indication
,
Gastrointestinal Disorders
,
Inflammatory Bowel Disease
,
Inflammatory Bowel Disease (IBD)
,
Natural compounds
,
Non-novel
,
Off-the-shelf
,
Predicted Novelty
,
Small Molecules
,
Targeted Therapy/Targeted Therapy
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Therapy Type
,
Ulcerative Colitis
,
Ulcerative Colitis (UC)
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Gastroenterology > Crohn's Disease
,
Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease
,
Clinical and Disease Specializations > Gastroenterology > Ulcerative Colitis
,
Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases
,
Clinical and Disease Specializations > Rare Diseases
,
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Technology Classifications > Therapeutic Modalities > Targets
,
Clinical and Disease Specializations > Gastroenterology
,
Clinical and Disease Specializations > Inflammation
,
Technology Classifications > Therapeutic Modalities
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum